Clinical characteristics of the 2 groups (OMG vs gOMG) before and after matching
| . | Unmatched . | Matched . | ||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics . | gOMG (n = 92) . | OMG (n = 73) . | P-value . | SDM . | gOMG (n = 65) . | OMG (n = 65) . | P-value . | SDM . |
| Gender, n (%) | 0.370a | 0.141 | 0.471a | 0.127 | ||||
| Male | 34 (37) | 32 (43.8) | 23 (35.4) | 27 (41.5) | ||||
| Female | 58 (63) | 41 (56.2) | 42 (64.6) | 38 (58.5) | ||||
| Age at onset (years), mean ± SD | 40.7 ± 17.6 | 41.6 ± 18.6 | 0.751b | 0.050 | 40.58 ± 17.96 | 41.86 ± 18.89 | 0.694c | 0.069 |
| Anti-AChR Ab, n (%) | 0.426a | 0.128 | 0.824a | 0.039 | ||||
| Positive | 70 (76.1) | 58 (79.5) | 52 (80) | 53 (81.5) | ||||
| Negative | 20 (21.7) | 12 (16.4) | 13 (20) | 12 (18.5) | ||||
| Unknown | 2 (2.2) | 3 (4.1) | 0 | 0 | ||||
| Time to TX (months), median (IQR) | 14 (8–26) | 10 (5–17) | 0.003d | 0.336 | 13 (7–24) | 11 (6–17) | 0.517e | 0.081 |
| Thymic histopathology, n (%) | 0.655a | 0.144 | 0.935a | 0.064 | ||||
| Presence of thymoma | 12 (13) | 13 (17.8) | 9 (13.8) | 10 (15.4) | ||||
| Presence of thymic hyperplasia | 29 (31.5) | 20 (27.4) | 16 (24.6) | 17 (26.2) | ||||
| Presence of involuted or normal thymus | 51 (55.4) | 40 (54.8) | 40 (61.5) | 38 (58.5) | ||||
| . | Unmatched . | Matched . | ||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics . | gOMG (n = 92) . | OMG (n = 73) . | P-value . | SDM . | gOMG (n = 65) . | OMG (n = 65) . | P-value . | SDM . |
| Gender, n (%) | 0.370a | 0.141 | 0.471a | 0.127 | ||||
| Male | 34 (37) | 32 (43.8) | 23 (35.4) | 27 (41.5) | ||||
| Female | 58 (63) | 41 (56.2) | 42 (64.6) | 38 (58.5) | ||||
| Age at onset (years), mean ± SD | 40.7 ± 17.6 | 41.6 ± 18.6 | 0.751b | 0.050 | 40.58 ± 17.96 | 41.86 ± 18.89 | 0.694c | 0.069 |
| Anti-AChR Ab, n (%) | 0.426a | 0.128 | 0.824a | 0.039 | ||||
| Positive | 70 (76.1) | 58 (79.5) | 52 (80) | 53 (81.5) | ||||
| Negative | 20 (21.7) | 12 (16.4) | 13 (20) | 12 (18.5) | ||||
| Unknown | 2 (2.2) | 3 (4.1) | 0 | 0 | ||||
| Time to TX (months), median (IQR) | 14 (8–26) | 10 (5–17) | 0.003d | 0.336 | 13 (7–24) | 11 (6–17) | 0.517e | 0.081 |
| Thymic histopathology, n (%) | 0.655a | 0.144 | 0.935a | 0.064 | ||||
| Presence of thymoma | 12 (13) | 13 (17.8) | 9 (13.8) | 10 (15.4) | ||||
| Presence of thymic hyperplasia | 29 (31.5) | 20 (27.4) | 16 (24.6) | 17 (26.2) | ||||
| Presence of involuted or normal thymus | 51 (55.4) | 40 (54.8) | 40 (61.5) | 38 (58.5) | ||||
Categorical variable expressed by number (percentage) and analysed by χ2 test.
Continuous variable summarized as mean ± SD and analysed by independent-samples for T-test.
Matched continuous variable summarized as mean ± SD and analysed by paired Student’s t-test.
Continuous variable summarized as median (IQR) and analysed by Mann–Whitney test.
Matched continuous variable summarized as median (IQR) and analysed by Wilcoxon signed-rank test.
Anti-AChR Ab: antibody against acetylcholinesterase receptor; IQR: interquartile range; OMG: ocular myasthenia gravis; SD: standard deviation; SDM: standardized difference in mean; TX: thymectomy; Unknown: not documented.
Clinical characteristics of the 2 groups (OMG vs gOMG) before and after matching
| . | Unmatched . | Matched . | ||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics . | gOMG (n = 92) . | OMG (n = 73) . | P-value . | SDM . | gOMG (n = 65) . | OMG (n = 65) . | P-value . | SDM . |
| Gender, n (%) | 0.370a | 0.141 | 0.471a | 0.127 | ||||
| Male | 34 (37) | 32 (43.8) | 23 (35.4) | 27 (41.5) | ||||
| Female | 58 (63) | 41 (56.2) | 42 (64.6) | 38 (58.5) | ||||
| Age at onset (years), mean ± SD | 40.7 ± 17.6 | 41.6 ± 18.6 | 0.751b | 0.050 | 40.58 ± 17.96 | 41.86 ± 18.89 | 0.694c | 0.069 |
| Anti-AChR Ab, n (%) | 0.426a | 0.128 | 0.824a | 0.039 | ||||
| Positive | 70 (76.1) | 58 (79.5) | 52 (80) | 53 (81.5) | ||||
| Negative | 20 (21.7) | 12 (16.4) | 13 (20) | 12 (18.5) | ||||
| Unknown | 2 (2.2) | 3 (4.1) | 0 | 0 | ||||
| Time to TX (months), median (IQR) | 14 (8–26) | 10 (5–17) | 0.003d | 0.336 | 13 (7–24) | 11 (6–17) | 0.517e | 0.081 |
| Thymic histopathology, n (%) | 0.655a | 0.144 | 0.935a | 0.064 | ||||
| Presence of thymoma | 12 (13) | 13 (17.8) | 9 (13.8) | 10 (15.4) | ||||
| Presence of thymic hyperplasia | 29 (31.5) | 20 (27.4) | 16 (24.6) | 17 (26.2) | ||||
| Presence of involuted or normal thymus | 51 (55.4) | 40 (54.8) | 40 (61.5) | 38 (58.5) | ||||
| . | Unmatched . | Matched . | ||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics . | gOMG (n = 92) . | OMG (n = 73) . | P-value . | SDM . | gOMG (n = 65) . | OMG (n = 65) . | P-value . | SDM . |
| Gender, n (%) | 0.370a | 0.141 | 0.471a | 0.127 | ||||
| Male | 34 (37) | 32 (43.8) | 23 (35.4) | 27 (41.5) | ||||
| Female | 58 (63) | 41 (56.2) | 42 (64.6) | 38 (58.5) | ||||
| Age at onset (years), mean ± SD | 40.7 ± 17.6 | 41.6 ± 18.6 | 0.751b | 0.050 | 40.58 ± 17.96 | 41.86 ± 18.89 | 0.694c | 0.069 |
| Anti-AChR Ab, n (%) | 0.426a | 0.128 | 0.824a | 0.039 | ||||
| Positive | 70 (76.1) | 58 (79.5) | 52 (80) | 53 (81.5) | ||||
| Negative | 20 (21.7) | 12 (16.4) | 13 (20) | 12 (18.5) | ||||
| Unknown | 2 (2.2) | 3 (4.1) | 0 | 0 | ||||
| Time to TX (months), median (IQR) | 14 (8–26) | 10 (5–17) | 0.003d | 0.336 | 13 (7–24) | 11 (6–17) | 0.517e | 0.081 |
| Thymic histopathology, n (%) | 0.655a | 0.144 | 0.935a | 0.064 | ||||
| Presence of thymoma | 12 (13) | 13 (17.8) | 9 (13.8) | 10 (15.4) | ||||
| Presence of thymic hyperplasia | 29 (31.5) | 20 (27.4) | 16 (24.6) | 17 (26.2) | ||||
| Presence of involuted or normal thymus | 51 (55.4) | 40 (54.8) | 40 (61.5) | 38 (58.5) | ||||
Categorical variable expressed by number (percentage) and analysed by χ2 test.
Continuous variable summarized as mean ± SD and analysed by independent-samples for T-test.
Matched continuous variable summarized as mean ± SD and analysed by paired Student’s t-test.
Continuous variable summarized as median (IQR) and analysed by Mann–Whitney test.
Matched continuous variable summarized as median (IQR) and analysed by Wilcoxon signed-rank test.
Anti-AChR Ab: antibody against acetylcholinesterase receptor; IQR: interquartile range; OMG: ocular myasthenia gravis; SD: standard deviation; SDM: standardized difference in mean; TX: thymectomy; Unknown: not documented.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
